Skip to content
Select language:
  • Español (ES)
  • العربية (AR)
Donate Fundraise
MS International
  • About MS

    About MS

    • What is MS?
    • Who gets MS?
    • Types of MS
    • MS in Children
    • Causes of MS
    • Diagnosing MS
    • Symptoms of MS

      Symptoms of MS

      • Bladder and bowel
      • Emotion and cognitition
      • Fatigue
      • Movement and coordination
      • Pain
      • Sexual problems
      • Vision
  • Living with MS

    Living with MS

    • Find MS support near you
    • MS, COVID-19 and vaccines – updated global advice
    • What influences quality of life with MS?

      What influences quality of life with MS?

      • Seven principles to improve quality of life
    • Treatments and therapies
    • Complementary and alternative therapies
    • Caregivers
    • Rehabilitation
    • Family life
    • Relationships and intimacy
    • Telling people you have MS
    • Ageing and MS
    • MS and menopause
    • Keeping healthy
    • Smoking and MS
    • Education and employment
    • International MS awards

      International MS awards

      • Award for people with MS
      • Award for caregivers
    • My story of MS

      My story of MS

      • Hao, China
      • Alexia, Cyprus
      • Hanin, Jordan
      • Ling, Malaysia
      • Artyom, Russia
      • Christelle, South Africa
      • Sean, UK
  • Research

    Research

    • AtlasofMS.org
    • Key topics in MS research

      Key topics in MS research

      • Clinical research and trials
      • MS registries
      • Patient Reported Outcomes for MS
      • Research into Progressive MS
      • Stem cell therapy for MS
      • Quality of life research in MS
    • Awards, grants and fellowships

      Awards, grants and fellowships

      • Du Pré Grants
      • McDonald Fellowships
      • Charcot Award
      • Young Investigator Award
      • Global MS research fellowships
  • Resources
  • News & events
  • About us

    About us

    • Who we are and what we do

      Who we are and what we do

      • Improving access to MS treatment and healthcare
      • Advocacy
    • Our strategy
    • Our members
    • Our progress
    • Our staff
    • How we are governed

      How we are governed

      • Board of trustees
      • Committees
      • International Medical and Scientific Board
    • How we are funded

      How we are funded

      • Our income in 2022
      • How we work with the healthcare industry
      • MSIF COVID-19 Response Initiative
      • Our supporter promise
    • Annual accounts and reviews
    • MSIF statement: War and Conflict’s impact on people affected by MS

      MSIF statement: War and Conflict’s impact on people affected by MS

      • Information for People affected by MS impacted by the war in Ukraine
    • Contact us
  • Get involved

    Get involved

    • Take part in an event
    • Join MSIF (MS organisations)
    • Join Against MS
    • Sign up for our newsletters
    • World MS Day
    • World Brain Day 2021
    • Cykelnerven
    • Our fundraisers
  • Get involved
  • Take part in an event
  • Join MSIF (MS organisations)
  • Join Against MS
  • Sign up for our newsletters
  • World MS Day
  • World Brain Day 2021
  • Cykelnerven
  • Our fundraisers
  • MSIF statement: War and Conflict’s impact on people affected by MS
  • Information for People affected by MS impacted by the war in Ukraine
  • How we are funded
  • Our income in 2022
  • How we work with the healthcare industry
  • MSIF COVID-19 Response Initiative
  • Our supporter promise
  • How we are governed
  • Board of trustees
  • Committees
  • International Medical and Scientific Board
  • Who we are and what we do
  • Improving access to MS treatment and healthcare
  • Advocacy
  • About us
  • Who we are and what we do
  • Our strategy
  • Our members
  • Our progress
  • Our staff
  • How we are governed
  • How we are funded
  • Annual accounts and reviews
  • MSIF statement: War and Conflict’s impact on people affected by MS
  • Contact us
  • Charcot Award
  • Charcot Award winners
  • McDonald Fellowships
  • McDonald Fellowship recipients
  • Du Pré Grants
  • Du Pré Grant recipients
  • Awards, grants and fellowships
  • Du Pré Grants
  • McDonald Fellowships
  • Charcot Award
  • Young Investigator Award
  • Global MS research fellowships
  • Key topics in MS research
  • Clinical research and trials
  • MS registries
  • Patient Reported Outcomes for MS
  • Research into Progressive MS
  • Stem cell therapy for MS
  • Quality of life research in MS
  • Research
  • AtlasofMS.org
  • Key topics in MS research
  • Awards, grants and fellowships
  • My story of MS
  • Hao, China
  • Alexia, Cyprus
  • Hanin, Jordan
  • Ling, Malaysia
  • Artyom, Russia
  • Christelle, South Africa
  • Sean, UK
  • Award for people with MS
  • James D Wolfensohn Award winners
  • International MS awards
  • Award for people with MS
  • Award for caregivers
  • What influences quality of life with MS?
  • Seven principles to improve quality of life
  • Living with MS
  • Find MS support near you
  • MS, COVID-19 and vaccines – updated global advice
  • What influences quality of life with MS?
  • Treatments and therapies
  • Complementary and alternative therapies
  • Caregivers
  • Rehabilitation
  • Family life
  • Relationships and intimacy
  • Telling people you have MS
  • Ageing and MS
  • MS and menopause
  • Keeping healthy
  • Smoking and MS
  • Education and employment
  • International MS awards
  • My story of MS
  • Symptoms of MS
  • Bladder and bowel
  • Emotion and cognitition
  • Fatigue
  • Movement and coordination
  • Pain
  • Sexual problems
  • Vision
  • About MS
  • What is MS?
  • Who gets MS?
  • Types of MS
  • MS in Children
  • Causes of MS
  • Diagnosing MS
  • Symptoms of MS
  • About MS
  • Living with MS
  • Research
  • Resources
  • News & events
  • About us
  • Get involved
  • Home
  • Tag: natalizumab

Tag: natalizumab

Natalizumab treatment may preserve upper limb function in secondary progressive MS

Results from a trial of natalizumab in secondary progressive MS suggest anti-inflammatory treatments could slow disability accumulation, even after significant function has been lost.

Alternative to natalizumab in people at risk of a brain infection

Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy

Natalizumab is more effective than fingolimod in reducing relapses

French researchers compare oral and injectable drugs for relapsing-remitting MS

Recommended treatment after stopping natalizumab

Switching from natalizumab to an alternative drug may prevent disease reactivation

Early identification of progressive multifocal leukoencephalopathy in patients on natalizumab

A method for early detection of Natalizumab-associated progressive multifocal leukoencephalopathy in the absence of clinical symptoms

Switching to second-line disease-modifying drugs

Study shows that switching to natalizumab is more effective than switching to fingolimod

Natalizumab improves walking in relapsing-remitting MS

Natalizumab is associated with clinically meaningful improvements in walking speeds

Better test for risk of PML infection in Natalizumab patients

The new test measures the risk of PML infection in people being treated with Natalizumab

Contact us

Multiple Sclerosis International Federation
3rd Floor
Skyline House
200 Union Street
London
SE1 0LX

Follow us

Keep in touch with our work on Twitter, Facebook and YouTube.

  • Twitter
  • Facebook
  • YouTube
Translate this site

Parts of this site are available in Arabic and Spanish. You can also use Google Translate. Read about our approach to translation.

  • Contact us
  • Terms & data protection
  • Privacy
  • Complaints
  • Whistleblowing
  • Site map

Company No: 05088553. Registered Charity No: 1105321